Mindset Pharma Announces Appointment of Clinician Scientist, Dr. Ishrat Husain, to Scientific Advisory Board
The safest recreational drug becomes even safer
Mindset Pharma Announces Additional Preclinical Results Suggesting Superior Efficacy and Improved Safety in Head-to-Head Comparison to Psilocybin for its First Lead Clinical Candidate, MSP-1014
Magic mushrooms are the safest recreational drug according to a recent study, but Mindset Pharma (MSET) is working to make them even safer.
The company found that its patent-pending psychedelic compound, MSP-1014, may be more effective, safer, and more scalable than psilocybin. Researchers discovered that MSP-1014 more than doubled the head twitch responses in mice, an indicator of serotonin 5-HT2A receptor activity, which is tied to psychedelic experiences. MSP-1014 did not cause body temperature to drop, which was seen with psilocybin.
If you missed the cannaBUS, jump on the psilocybin train
Maxim Group Gives Buy Rating To 10 Psychedelic Stocks: Compass, MindMed, Cybin, Field Trip And More
Now is the time to buy these 10 psychedelic stocks.
When the cannabis company GW Pharmaceuticals sold for billions earlier this year, those who didn’t invest were left with major regret. If you missed out on cannabis, now is your chance to be an early investor in the shroom boom as psychedelic companies begin to follow a similar pathway. These 10 companies are worth the buy according to Maxim Group’s latest analysis.
Maxim Group says Mindset Pharma is a ‘Buy’
Maxim Group initiates coverage of Mindset Pharma with a ‘Buy’ rating and price target of US$1
If you want to triple your investment in a year, keep an eye on Mindset Pharma. Mindset currently trades at C$0.45 in Canada (MSET) and US$0.36 in the States (MSSTF), but Maxim Group predicts that the price could go reach US$1 in 12 months, giving the company a ‘buy’ rating. Maxim analysts note that Mindset’s psilocybin compound, MSP-1014, is cheaper to produce than psilocybin and has a relatively short path to market, while Mindset’s other “purpose-designed” compounds could potentially be “best-in-class in the longer term.”
Mindset’s COPE program provides benchmark data to measure success of new psychedelic drug formulations
Mindset and InterVivo Solutions Announce Availability of First Preclinical Psychedelic Benchmark Data from COPE Program
The first psychedelic benchmark data was made available through the Cooperative Psychedelic Evaluation Platform (COPE), a program started by Mindset Pharma Inc. and InterVivo Solutions in March. The benchmark data is used to measure the success of new psychedelic drug formulations and “will undoubtedly help the value assessment of newer psychedelics in development”, according to Chief Scientific Officer of InterVivo. The data on psilocybin suggests that “the clinical exposure levels reported in humans correlates well to exposure and efficacy measures observed in mice”.